his month we saw the departure of 4 members of the Nonprescription Drugs Advisory Committee (NDAC) – which is a lot when you only had 6 members to begin with! Drs. Neil Farber.
This month we saw the departure of 4 members of the Nonprescription Drugs Advisory Committee (NDAC) – which is a lot when you only had 6 members to begin with! Drs. Neil Farber, Walid Gellad, Marcus Reidenberg and Consumer Representative Lorna Totman have all reached the end of their terms. Estela Pledge, M.S., a Health Education Specialist at the Alcohol and Drug Resource Center – Beu Health Center at Western Illinois University, has replaced Dr. Totman as the Consumer Representative. NDAC now has 11 vacancies. It will be interesting to see who FDA brings in for the NASACORT AQ Rx to OTC Switch AdComm on July 31!
This month, we also saw the following committee changes:
Stay tuned for our next blog post where we will put the spotlight on one of the hottest AdComms – the Cardiovascular and Renal Drugs AdComm.
ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact firstname.lastname@example.org.
Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more
FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more
One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more
US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us